Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | NMT2 | O60551 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.33 |
| ▸ | CHRNG | P07510 | 1/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.33 |
| ▸ | CHRND | Q07001 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20800966 | 0.89 | GLP1R (0.52) | GLP1RLPAR3LPAR1TLR2NMT2 | |
| SCHEMBL20375678 | 0.87 | GLP1R (0.53) | GLP1RLPAR3LPAR1TLR2TSHR | |
| SCHEMBL18715649 | 0.87 | GLP1R (0.54) | GLP1RLPAR3LPAR1TLR2NMT2 | |
| SCHEMBL23714526 | 0.86 | GLP1R (0.50) | GLP1RLPAR3LPAR1TLR2NMT2 | |
| SCHEMBL20375509 | 0.86 | GLP1R (0.53) | GLP1RLPAR3LPAR1TLR2NMT2 | |
| SCHEMBL21287416 | 0.85 | GLP1R (0.54) | GLP1RLPAR3LPAR1TLR2CHRNA1 | |
| SCHEMBL22404807 | 0.84 | GLP1R (0.54) | GLP1RLPAR3LPAR1TLR2CHRNA1 | |
| SCHEMBL18708280 | 0.84 | GLP1R (0.53) | GLP1RLPAR3LPAR1TLR2NMT2 | |
| SCHEMBL20370974 | 0.83 | GLP1R (0.52) | GLP1RLPAR3LPAR1TLR2NMT2 | |
| SCHEMBL22453873 | 0.81 | GLP1R (0.48) | GLP1RLPAR3LPAR1TLR2NMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238602-A1 | RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238602-A1 | RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use | TEK, PLIN3, PNLIP | GLP1R 459/4885LPAR3 123/4885LPAR1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.